Malaysia’s intensified push to expand the use of generic medicines is set to reshape prescribing practices, procurement priorities and pharmaceutical market dynamics, according to a new report by BMI.
The policy shift is expected to accelerate growth in the generics segment while increasing competitive pressure on innovative drugmakers seeking to expand in the country.
BMI noted that Malaysia’s health authorities have adopted a “generic-first” prescribing approach, where generic alternatives are prioritised once patent protections for originator drugs expire.
In January 2026, the health minister said the government had saved more than RM900 million over the past two years by prioritising generic medicines across both public and private healthcare settings.
The initiative forms part of the National Generic Medicines Framework, which aims to build public confidence in generics, reshape clinicians’ prescribing behaviour and improve affordability of treatment.
Key measures include public awareness programmes, price transparency tools for consumers, generic-name labelling in public healthcare facilities and strict regulatory standards such as bioequivalence requirements.
Procurement to favour lower-cost treatments
Public healthcare spending trends are also reinforcing the shift. Although Malaysia’s overall 2026 federal budget is set to decline, allocations for the Ministry of Health rose to RM46.5 billion, reflecting continued emphasis on healthcare access and cost containment.
BMI expects public-sector procurement to increasingly favour generic medicines and biosimilars, aligning with broader policy priorities outlined in the 13th Malaysia Plan (2026–2030) and the Health White Paper.
This approach is likely to support wider access to essential therapies while helping the government manage rising healthcare expenditure.
Support for local pharmaceutical production
The government is also expected to intensify support for domestic drug manufacturing under the New Industrial Master Plan (NIMP) 2030.
Policies such as procurement preference for locally produced medicines and critical medical devices are aimed at strengthening supply security and improving the government’s leverage in price negotiations.
BMI said these measures will accelerate the transition toward cost-effective, locally produced generic medicines, reinforcing the segment’s expansion in Malaysia’s pharmaceutical market.
However, the growing focus on affordability and domestic production could limit growth opportunities for multinational innovative drugmakers, particularly in publicly funded healthcare segments.
